HomeStock ScreenerCaplin Point Laboratories

Caplin Point Laboratories Share Price | Caplin Point Laboratories Stock Screener

CAPLIPOINT Pharmaceuticals
Share Price NSE
₹2023.30
▼ -12.50 (-0.61%)
2026-05-27 00:00:00
Share Price BSE
₹2024.50
▼ -10.95 (-0.54%)
2026-05-27 00:00:00
As of May 27, 2026, the Caplin Point Laboratories share price (NSE: CAPLIPOINT) is ₹2,023.30 on NSE and ₹2,024.50 on BSE, down 0.61% from the previous close, with shares trading between ₹2,014.60 and ₹2,063.70, and a 52-week range of ₹1,504.80–₹2,343.00. Check CAPLIPOINT 52-week chart for the annual price range and momentum. Use the Caplin Point Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Caplin Point Laboratories Market Cap ₹15,415.20 Cr.
CAPLIPOINT P/E Ratio (TTM) 23.73
Caplin Point Laboratories P/B Ratio 4.30
EPS (TTM) ₹84.36
Dividend Yield 0.20%
Debt to Equity -
CAPLIPOINT 52 Week High ₹2343.00
Caplin Point Laboratories 52 Week Low ₹1504.80
Operating Margin 34.00%
Profit Margin 27.50%
CAPLIPOINT Revenue (TTM) ₹629.00
EBITDA ₹233.00
Net Income ₹173.00
Total Assets ₹4,046.00
Total Equity ₹3,586.00

Caplin Point Laboratories Share Price Chart

Screen Caplin Point Laboratories share price with an interactive chart. Analyse CAPLIPOINT price trends and volatility across different timeframes.

Caplin Point Laboratories Company Profile - Fundamental Screener

Screen Caplin Point Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for CAPLIPOINT shares.
Caplin Point Laboratories Limited is an Indian pharmaceutical company founded in 1990. It develops, produces, and markets generic formulations and branded products globally. The company has manufacturing facilities in India and serves markets in Latin America, Africa, the USA, and the European Union. Caplin Point specializes in various pharmaceutical formulations,...more
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
Chairperson/CEO C C Paarthipan
ISIN INE475E01026

Caplin Point Laboratories Balance Sheet Screener

Screen CAPLIPOINT balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017
Assets
Total Assets 4,046 3,208 2,698 2,191 1,736 1,364 1,126 743 501 358
Current Assets 2,586 2,134 1,893 1,552 1,298 1,015 823 494 304 179
Fixed Assets 814 546 453 280 287 305 273 227 170 152
Liabilities
Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 29 16 20 16 19 17 25 23 28 20
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 3,586 2,886 2,347 1,907 1,510 1,203 957 633 364 225
Share Capital 15 15 15 15 15 15 15 15 15 15
Reserves & Surplus 3,571 2,619 2,084 1,649 1,252 954 716 514 349 210

Caplin Point Laboratories Income Statement Screener - Profit & Revenue Analysis

Screen Caplin Point Laboratories income statement and profit fundamentals. Analyze CAPLIPOINT quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Caplin Point Laboratories share price evaluation.
Item 2026-Mar 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar 2022-Jun
Revenue 629 528 533 564 577 471 478 504 524 401 407 431 453 351 360
Expenses 396 334 333 345 353 308 307 318 331 265 269 273 293 239 244
EBITDA 233 194 201 220 223 163 170 185 194 135 139 158 160 111 116
Operating Profit % 34.00% 33.00% 35.00% 35.00% 35.00% 32.00% 33.00% 34.00% 33.00% 32.00% 32.00% 34.00% 33.00% 29.00% 30.00%
Depreciation 19 17 16 18 19 16 16 17 16 11 11 12 14 11 11
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 213 177 185 201 204 146 154 169 177 124 127 146 145 100 105
Tax 41 31 34 41 38 25 30 38 37 23 23 30 26 19 19
Net Profit 173 145 151 160 166 121 125 131 140 101 104 116 120 81 86
EPS 22.38 18.75 20.10 20.32 21.56 16.01 16.32 17.22 18.28 13.45 13.62 15.13 15.44 10.43 11.21

Caplin Point Laboratories Cash Flow Screener - Liquidity Fundamentals

Screen CAPLIPOINT cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March
Operating Activities 432 318 271 337 269 45 83 67 68 42
Investing Activities -333 -319 -216 -377 -30 -54 -100 -69 -36 -6
Financing Activities -38 -38 -28 -41 -24 80 90 -12 -7 -14
Net Cash Flow 61 -39 27 -81 215 70 74 -14 25 23

Caplin Point Laboratories Shareholding Pattern Screener

See Caplin Point Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Caplin Point Laboratories promoter holding and ownership changes for CAPLIPOINT on TickJournal.
Item 2026-Mar 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept
Promoter Holding 70.57% 70.56% 70.56% 70.57% 70.57% 70.62% 70.56% 70.56%
FII Holding 6.15% 5.73% 6.17% 6.51% 6.59% 3.34% 3.37% 3.70%
DII Holding 2.14% 2.01% 2.22% 2.10% 2.05% 1.09% 1.49% 1.84%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 14.46% 15.11% 14.32% 14.20% 14.13% 17.59% 17.50% 17.12%
Other Holding 6.68% 6.59% 6.73% 6.61% 6.65% 7.36% 7.08% 6.78%
Shareholder Count 93,896 96,387 94,169 93,753 93,705 81,409 80,411 96,123

Caplin Point Laboratories Share Dividend Screener - Share Yield Analysis

Check Caplin Point Laboratories dividend history with payout and yield data. View Caplin Point Laboratories dividend details including ex-dates and amounts for CAPLIPOINT stock.
Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹6.00 0.40%
2024-March ₹5.00 0.25%
2023-March ₹4.50 0.34%
2022-March ₹4.00 0.68%
2021-March ₹3.00 0.44%
2020-March ₹2.50 0.62%
2019-March ₹2.20 0.78%
2018-March ₹2.00 0.50%
2017-March ₹1.50 0.26%

Caplin Point Laboratories Stock Index Membership

See which indices include Caplin Point Laboratories stock. Check CAPLIPOINT index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100
NIFTY MIDSML 400
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY SMALLCAP250 QUALITY 50
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP
NIFTY500 MULTICAP MOMENTUM QUALITY 50

Caplin Point Laboratories Market Events Screener - Corporate Actions

Get Caplin Point Laboratories corporate actions including splits, bonuses, and buybacks. Check Caplin Point Laboratories stock events that may affect CAPLIPOINT share price.
Announcement Date Record Date Event Type Information Price Impact
Annual General Meeting NA 23.73%
Dividend ₹ 2.50 /share 25.36%
Dividend ₹ 1.50 /share 0.54%
Annual General Meeting NA 21.61%
Dividend ₹ 2.00 /share -11.76%
Dividend ₹ 3.00 /share 16.01%
Dividend ₹ 2.50 /share 5.25%
2026-05-29 2026-05-30 Dividend ₹ 4.00 /share 10.15%
2026-05-14 2026-05-14 Quarterly Result Announcement NA 0.13%
2026-02-05 2026-02-05 Quarterly Result Announcement NA 10.82%
2025-11-05 2025-11-05 Quarterly Result Announcement NA -0.63%
2025-08-07 2025-08-07 Quarterly Result Announcement NA -7.68%
2025-05-30 2025-05-30 Dividend ₹ 3.00 /share 7.28%
2025-05-15 2025-05-15 Quarterly Result Announcement NA 8.60%
2025-02-07 2025-02-07 Quarterly Result Announcement NA 6.87%

Caplin Point Laboratories Competitors Screener - Peer Comparison

Screen CAPLIPOINT competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 442,581 40.42 58,220 6.38% 11,565 54.75
Divis Laboratories 182,828 73.73 10,560 8.73% 2,520 66.48
Torrent Pharmaceuticals 151,833 66.80 13,753 19.18% 2,028 61.90
Cipla 113,025 29.26 27,712 -2.46% 3,783 61.92
Dr Reddys Laboratories 109,105 26.24 33,593 -0.44% 3,998 52.61
Zydus Life Science 104,543 20.40 26,720 13.65% 5,242 69.40
Lupin 104,288 19.46 27,488 19.98% 5,345 47.33
Mankind Pharma 102,351 52.84 14,278 12.03% 1,750 62.34
Aurobindo Pharma 85,000 24.29 33,385 3.21% 3,376 52.91
Laurus Labs 72,530 81.46 6,813 21.03% 884 77.10

Caplin Point Laboratories Company Announcements - News Screener

Screen CAPLIPOINT latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-05-27 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-05-26 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-05-19 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-05-19 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-05-19 Corporate Action-Board approves Dividend -
2026-05-19 Financial Results For The Quarter And Year Ended March 31 2026 -
2026-05-19 Board Meeting Outcome for For Meeting Held On May 14 2026 -
2026-05-07 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-05-07 Board Meeting Intimation for Approval Of Financial Results And Declaration Of Interim Dividend If Any Approved By The Board. -
2026-05-05 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-04-06 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-03-27 Closure of Trading Window -
2026-03-13 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-03-03 Announcement under Regulation 30 (LODR)-Cessation -
2026-02-28 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-02-24 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-02-11 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-02-05 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-02-05 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-02-05 Financial Results For The Quarter Ended December 31 2025 -